Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28


G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, Shohet JM.

Cancer Res. 2015 Jun 15;75(12):2566-79. doi: 10.1158/0008-5472.CAN-14-2946. Epub 2015 Apr 23.


Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS.

Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.


The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.

Wang J, Yin D, Xie C, Zheng T, Liang Y, Hong X, Lu Z, Song X, Song R, Yang H, Sun B, Bhatta N, Meng X, Pan S, Jiang H, Liu L.

Oncotarget. 2014 Sep 30;5(18):8478-91.


Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.

Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y, Jiang C, Ding Y.

Biomed Res Int. 2014;2014:764981. doi: 10.1155/2014/764981. Epub 2014 Jun 25.


Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling.

Choi YK, Cho SG, Woo SM, Yun YJ, Park S, Shin YC, Ko SG.

Mediators Inflamm. 2014;2014:492173. doi: 10.1155/2014/492173. Epub 2014 May 25.


Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.

Peng HS, Liao MB, Zhang MY, Xie Y, Xu L, Zhang YJ, Zheng XF, Wang HY, Chen YF.

PLoS One. 2014 Jun 23;9(6):e100814. doi: 10.1371/journal.pone.0100814. eCollection 2014.


Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.

Chen D, Wei L, Yu J, Zhang L.

Clin Cancer Res. 2014 Jul 1;20(13):3472-84. doi: 10.1158/1078-0432.CCR-13-2944. Epub 2014 Apr 24.


A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.

Aparicio J, García-Mora C, Martín M, Petriz ML, Feliu J, Sánchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J.

PLoS One. 2014 Jan 9;9(1):e82209. doi: 10.1371/journal.pone.0082209. eCollection 2014.


The role of cell signalling in the crosstalk between autophagy and apoptosis.

Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P.

Cell Signal. 2014 Mar;26(3):549-55. doi: 10.1016/j.cellsig.2013.11.028. Epub 2013 Dec 2. Review.


Ion-current-based proteomic profiling of the retina in a rat model of Smith-Lemli-Opitz syndrome.

Tu C, Li J, Jiang X, Sheflin LG, Pfeffer BA, Behringer M, Fliesler SJ, Qu J.

Mol Cell Proteomics. 2013 Dec;12(12):3583-98. doi: 10.1074/mcp.M113.027847. Epub 2013 Aug 26.


Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.

Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y.

BMC Cancer. 2013 Jul 29;13:363. doi: 10.1186/1471-2407-13-363.


Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.

Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W.

Br J Cancer. 2013 Jul 23;109(2):342-50. doi: 10.1038/bjc.2013.334. Epub 2013 Jun 27.


Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.

Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.

Br J Pharmacol. 2013 Feb;168(3):658-72. doi: 10.1111/j.1476-5381.2012.02212.x.


Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Wachsmann MB, Pop LM, Vitetta ES.

J Investig Med. 2012 Apr;60(4):643-63. doi: 10.231/JIM.0b013e31824a4d79. Review.


Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Oh SJ, Erb HH, Hobisch A, Santer FR, Culig Z.

Endocr Relat Cancer. 2012 May 3;19(3):305-19. doi: 10.1530/ERC-11-0298. Print 2012 Jun.


Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis.

Huang C, Xie K.

Cytokine Growth Factor Rev. 2012 Feb-Apr;23(1-2):25-35. doi: 10.1016/j.cytogfr.2012.01.003. Epub 2012 Feb 16. Review.


Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.

Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L.

Oncogene. 2012 Nov 15;31(46):4848-58. doi: 10.1038/onc.2011.644. Epub 2012 Jan 30.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk